2023 Boca Raton Regional Hospital Internal Medicine Symposium Evaluation - Day 2

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence Not applicable|Not applicable

	5	4	3	2	1	Not applicable
Discuss the treatment options for NERD.	Discuss the treatment options for NERD. - 5	Discuss the treatment options for NERD. - 4	Discuss the treatment options for NERD. - 3	Discuss the treatment options for NERD. - 2	Discuss the treatment options for NERD. - 1	Discuss the treatment options for NERD. - Not applicable
Outline a screening and diagnostic algorithm for NAFLD.	Outline a screening and diagnostic algorithm for NAFLD. - 5	Outline a screening and diagnostic algorithm for NAFLD. - 4	Outline a screening and diagnostic algorithm for NAFLD. - 3	Outline a screening and diagnostic algorithm for NAFLD. - 2	Outline a screening and diagnostic algorithm for NAFLD. - 1	Outline a screening and diagnostic algorithm for NAFLD. - Not applicable
Differentiate symptomatic Long Covid from ongoing non-infectious risks.	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - 5	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - 4	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - 3	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - 2	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - 1	Differentiate symptomatic Long Covid from ongoing non-infectious risks. - Not applicable
Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy.	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - 5	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - 4	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - 3	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - 2	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - 1	Classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy. - Not applicable
Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis.	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - 5	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - 4	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - 3	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - 2	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - 1	Review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis. - Not applicable

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Rheumatology Year in Review - Benjamin Wang, MD	Rheumatology Year in Review - Benjamin Wang, MD - 5	Rheumatology Year in Review - Benjamin Wang, MD - 4	Rheumatology Year in Review - Benjamin Wang, MD - 3	Rheumatology Year in Review - Benjamin Wang, MD - 2	Rheumatology Year in Review - Benjamin Wang, MD - 1	Rheumatology Year in Review - Benjamin Wang, MD - NA
Sarcoidosis Update - Benjamin Wang, M.D.	Sarcoidosis Update - Benjamin Wang, M.D. - 5	Sarcoidosis Update - Benjamin Wang, M.D. - 4	Sarcoidosis Update - Benjamin Wang, M.D. - 3	Sarcoidosis Update - Benjamin Wang, M.D. - 2	Sarcoidosis Update - Benjamin Wang, M.D. - 1	Sarcoidosis Update - Benjamin Wang, M.D. - NA
Leishmaniasis - Ravi Durvasula, M.D.	Leishmaniasis - Ravi Durvasula, M.D. - 5	Leishmaniasis - Ravi Durvasula, M.D. - 4	Leishmaniasis - Ravi Durvasula, M.D. - 3	Leishmaniasis - Ravi Durvasula, M.D. - 2	Leishmaniasis - Ravi Durvasula, M.D. - 1	Leishmaniasis - Ravi Durvasula, M.D. - NA
Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - 5	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - 4	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - 3	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - 2	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - 1	Artificial Intelligence in GI - Michael B. Wallace, M.D., MPH - NA
Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D.	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - 5	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - 4	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - 3	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - 2	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - 1	Nonerosive Reflux Disease (NERD) - Karthik Ravi, M.D. - NA
Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D.	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - 5	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - 4	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - 3	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - 2	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - 1	Update on Nonalcoholic Steatohepatitis (NASH) - K. Rajender Reddy, M.D. - NA
Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D.	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - 5	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - 4	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - 3	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - 2	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - 1	Covid Three Years Later: The Long Tail of Long Covid - Robert M. Wachter, M.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will apply treatment options for NERD.

I will apply a screening and diagnostic algorithm for NAFLD.

I will differentiate symptomatic Long Covid from ongoing non-infectious risks.

I will classify polyp, detect early pancreas cancer, and optimize workflow of capsule endoscopy.

I will review the major findings regarding drug therapies in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

What, if any, new skills/strategies will you apply in your clinical practice? *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

Attestation *

Choose 1 option

I attest that I have participated in this live virtual symposium in its entirety.

I attest that I have participated in _____ hours of instruction during this live webinar.

hours attestation *

Hours attended

You are here

2023 Boca Raton Regional Hospital Internal Medicine Symposium Evaluation - Day 2